Algert Global’s bluebird bio BLUE Stock Holding History

Algert Global’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,353	Closed	-$946K	–	418
2020 Q3	$946K	Buy	+1,353	New	+$1.06M	0.3%	134

Other funds holding BLUE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Algert Global's BLUE Position: Q4 2020 in Review

Algert Global sold out of bluebird bio (BLUE) in Q4 2020, closing a stake of 1,353 shares — an estimated $946K sold.

Algert Global first reported a position in BLUE in Q3 2020 and held it in 1 quarter. The position peaked at $946K in Q3 2020. 262 funds tracked by Wall St. Rank hold BLUE as of Q4 2020.

Algert Global reported no remaining bluebird bio position as of Q4 2020 after selling out during the quarter.
Algert Global sold 1,353 bluebird bio shares in Q4 2020, an estimated $946K.
Algert Global first reported a position in bluebird bio in Q3 2020 and held it in 1 quarter.
Algert Global's bluebird bio position peaked at $946K in Q3 2020.
262 funds tracked by Wall St. Rank held bluebird bio as of Q4 2020.

Based on Algert Global's 13F filing for Q4 2020, filed 12 Feb 2021.